A retrospective, cohort study analyzing difference in clinical and endoscopic outcomes for UST or VDZ as a monotherapy compared to a combination with thiopurines or methotrexate
Latest Information Update: 29 Nov 2022
At a glance
- Drugs Ustekinumab (Primary) ; Vedolizumab (Primary) ; Methotrexate; Purines
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 29 Nov 2022 New trial record
- 11 Oct 2022 Primary endpoint has not been met. (clinical remission or response as calculated by partial MAYO score (remission 3, response is a decrease 1) for UC or Harvey Bradshaw Index for CD (remission 5, response is a decrease 2) at week 52, as per Results presented at the 30th United European Gastroenterology Week
- 11 Oct 2022 Primary endpoint has not been met. (clinical remission or response as calculated by partial MAYO score (remission 3, response is a decrease 1) for UC or Harvey Bradshaw Index for CD (remission 5, response is a decrease 2) at week 26), as per Results presented at the 30th United European Gastroenterology Week